We are live on ! Find out more
PSC

Patient Square Capital Portfolio holdings

AUM $564M
1-Year Est. Return 261.3%
This Fund
S&P 500
This Quarter Est. Return
+79.9%
1 Year Est. Return
+261.3%
3 Year Est. Return
+328.19%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$374M
AUM Growth
+$96.5M
Cap. Flow
-$11M
Cap. Flow %
-2.95%
Top 10 Hldgs %
85.56%
Holding
27
New
8
Increased
6
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$9.31M
2
CDTX
Cidara Therapeutics
CDTX
+$6.76M
3
CELC icon
Celcuity
CELC
+$4M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$3.19M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$2.98M

Top Sells

Rank Stock Value
1
LQDA icon
Liquidia Corp
LQDA
+$13.4M
2
ARGX icon
argenx
ARGX
+$8.9M
3
CGEM icon
Cullinan Oncology
CGEM
+$6.54M
4
SRRK icon
Scholar Rock
SRRK
+$5.45M
5
INSM icon
Insmed
INSM
+$3.97M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
26
Scholar Rock
SRRK
$5.71B
– –
-154,000
Closed -$5.45M
YARW
27
Yarrow Bioscience, Inc. Common Stock
YARW
$24.9M
– –
-6,341
Closed -$523K
1
2

Similar funds

TCP
ThornTree Capital Partners Boston, Massachusetts $564M AUM 36.37% 1-Year Est. Return
AHSW
Adventist Health System West Roseville, California $564M AUM 17.1% 1-Year Est. Return
KF
KKM Financial Chicago, Illinois $563M AUM 28.2% 1-Year Est. Return
KBG
Kahn Brothers Group New York $564M AUM 25.3% 1-Year Est. Return
AAS
Asset Allocation Strategies Farmington, Michigan $563M AUM 15.65% 1-Year Est. Return
LC
Lavaca Capital Houston, Texas $564M AUM 4.6% 1-Year Est. Return
AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $563M AUM 20.97% 1-Year Est. Return
OC
Opal Capital Boca Raton, Florida $565M AUM

Patient Square Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Patient Square Capital held 27 positions worth $374M, up 35% from $277M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Patient Square Capital's Q3 2025 filing shows 8 new, 6 increased, 8 reduced and 3 closed positions. Its largest new stake was Abivax: 151,833 shares worth $12.9M. The largest sale was Liquidia Corp, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Patient Square Capital's largest Q3 2025 buy was Abivax: 151,833 shares worth $12.9M.
  • Patient Square Capital added most to Cidara Therapeutics in Q3 2025, an estimated $6.76M increase.
  • Patient Square Capital's biggest Q3 2025 reduction was Liquidia Corp, cutting an estimated $13.4M.
  • Patient Square Capital fully exited Cullinan Oncology in Q3 2025, selling an estimated $6.54M.
  • Patient Square Capital's ten largest holdings make up 86% of its $374M portfolio in Q3 2025.
  • Patient Square Capital opened 8 new positions and closed 3 in Q3 2025.
  • Patient Square Capital's portfolio value rose 35% quarter-over-quarter to $374M.

Based on Patient Square Capital's 13F filing for Q3 2025, filed 10 Nov 2025.